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Abstract
Objective: The objective of this systematic review is to see how effective and safe is
Acetyl-L-Carnitine in treating children with ADHD.
Study Design: This systematic review evaluated 3 randomized, controlled and double
blind articles all published in English, which were published in peer-reviewed journals.
The articles were found on PubMed through PCOM’s library website.
Outcomes measured: This review assessed how safe and effective ALC would be in
treating children with ADHD. The outcomes were measured using the Parent and
Teacher ADHD Scale IV, Conners’ Global Index-Parents Scale, Conners’ Global Index –
Teachers Scale and the Vineland scores as well. These scales measure the behavior and
attention of the child. This study also measured side effects such as psychic, neurologic,
autonomic and other side effects to determine how safe this medication was.
Results: Based on all three studies conducted, it was determined that ALC combined
with methylphenidate was ineffective in treating children with ADHD but it did prove to
be safe and help to prevent side effects such irritability and headache. It was also
determined that ALC alone without any other medications, was not effective and did not
have a great impact on treating the behavior and attention of the children as well. The
only significant finding showed that the children being treated with ALC alone were
more prone to headaches compared to the group being treated with the placebo alone.
However, ALC worked better in children with the inattentive type of ADHD compared to
how it worked in children with the combined type of inattention and hyperactivity. ALC
also worked very well to improve the symptoms of children with not only ADHD but
also Fragile X Syndrome.
Conclusion: In the end, it was determined that combined with methylphenidate, ALC
would not be considered an effective treatment to help improve the behavior of children
with ADHD. ALC used alone without any other medication was also determined to be
ineffective in treating the behavior symptoms of ADHD. It was found that ALC actually
might be more beneficial for treatment for a certain type of ADHD, like the inattentive
type. ALC was proven to also have great improvement in the inattention and social skills
of children, not only with ADHD, but also with Fragile X Syndrome and more studies
could be done to see how well this would work in children with Autism.
Key Words: “ADHD”, ”attention-deficit hyperactive disorder”, ”ALC”, “Acetyl-LCarnitine”
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Introduction
Attention deficit hyperactivity disorder contains 3 categories, which include an
inattentive type, an impulsive type and a hyperactive type.4 The inattentive type is used
mostly to describe children who have trouble staying focused and are easily distracted.4
The inattentive type might just walk away from responsibilities and tasks and they lack
perseverance.5 Their work ethic may be all over the place due to the fact that they are
disorganized. These children may also have behavior issues and may be defiant. They
may also show a lack of comprehension of academics in school or a lack of
comprehension of general things dealt with in life.5 Children with the inattentive type
may also be forgetful and lose things very easily, especially when they place something
down because they may not be able to remember where they placed that item.4 The
impulsive type is used to describe children who make careless decisions without putting
much though into those decisions. They can act on a whim, in a way that is careless and
may seem inpatient at times. They may also find it hard to wait their turn in school or
when playing games with other people at school.4 The hyperactive type describes children
who cannot sit still such as children who always fidget while seating down or who are
restless.4 Restless behaviors can be displayed in ways such as tapping on the desk at
school or talking during quiet time in school or climbing furniture at home.5
In adults this can be displayed as the constant need to move or swing the legs
back and forth.5 This may not allow the child to be able to sit still during class long
enough to be beneficial.5 They always feel the need to move or walk around and these
symptoms can manifest at home, school or anywhere else. 4 They always feel the need to
move even if the place and time is not appropriate.5 The impulsive type will make quick
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decisions in the moment without thinking about the consequences affecting them or
people around them. They may not even realize that some decisions they make carry a lot
of harm that make impact their lives or the lives of others.4 They also assume if they
make quick and fast decisions they will be rewarded and will receive instant
gratification.5
Teenagers with ADHD are more likely to have conflict with their friends, and
tend to be more aggressive.4 They are more likely to become involved in crime, drink,
smoke and use other drugs, which would further impact their decision making skills.4
These children are not only impulsive in their actions but they also can be impulsive in
their social interactions and conversations. These children may find that when conversing
with other people, they tend to interrupt others while they are talking and they can also be
intrusive.5
People with ADHD may present with all of these types but may also present with
one or two of these types.4 Some people may be affected by the inattentive type of
ADHD, due to fact that they can’t stop daydreaming.4 The most common presentation of
this condition is the inattentive type combined with the hyperactive behavior in older
children.4 In younger children, such as preschool age, the hyperactive type may present
first.4 It is expected that sometimes people may not be able to focus all the time or stop
moving around, but if these behaviors get to the point where they interact with your
quality of life, especially at home and at school, then it may be ADHD.5 Most people
have this condition starting from a very young age but symptoms can change as people
age and become older. Teenagers and adults with ADHD will be less hyperactive but will
often feel restless.5
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Scientists are unsure of what exactly causes this disorder and it’s symptoms but it
has been proven that many things can lead to the development of this condition. In
children with this condition, research has shown that low dopamine levels also affects the
child and their learning abilities.7 The chemical is transported between the nerves of the
cells in the brain, and is more used in the regions of the brain that deal with learning and
memory.7 It has also been proven that our social environment can affect children too as
well. ADHD can sometimes manifest from lack of exercise, huge emphasis on
achievement and any change in the child’s family situation at home.7 Certain foods can
play a role too in developing this, such as in children who eat many food containing
artificial flavoring and preservatives.7
Genes have proven to play a part in the development of this condition because
ADHD can be hereditary.7 Any substance used during pregnancy can lead to an increased
risk of the child developing ADHD such as cigarette smoking, alcohol use or controlled
substance use. Any risk to fetus causing low birth weight, lack of oxygen at birth or brain
injuries might cause this condition too.7 Exposure to environmental toxins such as high
levels of lead, at a young age, can lead to this development as well.7 It has been shown
that this condition is more common in males than females but this does not exclude the
fact that females can get this condition too.4 If it does present in a female, they tend to
have more issues with attention compared to being hyperactive.4 Many people with
ADHD can also have other conditions associated with them such as various other type of
learning disabilities, anxiety disorders, conduct disorders due to the impulsive behavior,
depression, and substance abuse.4
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Unfortunately, the economic cost of ADHD is very high due to the fact that 9.5 %
of children that are between the ages 4-17 years old have been diagnosed with ADHD.6
27% of all the costs of ADHD are due to education and the healthcare associated with
this condition.6 Children with ADHD need more attention in school, which leads to more
education costs for programs such as special education, occupation and speech therapy
and school counseling.6 These children also need more healthcare visits to adjust
medications and monitor progress, which can cost up to 18.04 billion dollars total per
year.6 First line medications are usually considered to be psychostimulants for this
disorder.8 These stimulants include amphetamine-based drugs such as Dexedrine,
Adderall and Vyvanse.8 Stimulants also include methylphenidate-based medications such
as Ritalin (methylphenidate), Biphentin and Concerta.8 Non-stimulant drugs can be used
as well such as Strattera (atomoxetine) and Intuniv (guanfacine) for patients that do not
want to use stimulants or when stimulants fail.8
Objective
The objective of this systematic review is to see how effective and safe is AcetylL-Carnitine in treating children with ADHD.
Methods
This systematic review evaluated 3 randomized, controlled and double blind
articles all published in English, which were published in peer-reviewed journals. The
articles were found on PubMed through PCOM’s library website. The articles were
selected based on their time frame and how much the information in the articles could
help answer my question. They were also selected on whether they discussed patient
oriented evidence that matters (POEMs). The articles were found using the key words
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“ADHD” and “Acetyl-L-Carnitine”. All patients in all 3 of the studies were over the age
of 5 and under the age of 13 years, previously diagnosed with ADHD. The intervention
used was Acetyl-l-Carnitine in weight based doses from 500 to 1500 mg b.i.d.
In study conducted by Abbasi et al. from 2011, the first group was treated with
acetyl-l-carnitine plus methylphenidate at a dose of 20 -30 mg/day depending on their
weight. The second group was treated with just acetyl-l-carnitine at a dose of 20-30
mg/day depending on their weight.
In study conducted by Arnold et al. from 2007, the first group was treated with
acetyl-l-carnitine at a dose of 500-1500 mg/day depending on weight while the second
group was being treated with the placebo at a dose of 500-1500 mg/day depending on the
weight.
In study conducted by Torrioli et al. from 2008, the first group contained only
boys aged 6 to 13 years old that had ADHD but also had Fragile X syndrome. They were
treated with Acetyl –l- Carnitine at 500 mg twice daily while the second group had the
same conditions but they were treated with a placebo at the same dose. P-values,
ANOVA, t-values, standard deviations were used in the following articles.
Table 1 –Demographics and characteristics of included studies
Study

Type

#Pts Age
(yrs)

Inclusion
criteria

Exclusion
criteria

W/D Intervention

Abbasi1
(2011)

Double
blind
RCT

40

40 outpatients,
which included
28 boys and 12
girls, between
the ages of 713 who met the
DSM-IV-TR
diagnostic
criteria for
ADHD

Were excluded
if they had a
history or
current
diagnosis of
pervasive
developmental
disorders,
schizophrenia,
or other
psychiatric

2

Between
the ages
of 7-13

Methylphenidate
plus Acetyl –lCarnitine

	
  
	
  

	
  

2

Arnold
(2007)

Double
blind
RCT

112

Torrioli3 Double 63
(2008)
blind
RCT

Ages 5
to 12

Confirmed by
the Diagnostic
Interview
Schedule for
children
(DISC-IV); an
item mean on
either the 18
DSM-IV
ADHD
symptoms

Ages 6
– 13
years

Patients were
recruited
through genetic
clinics and
were included
when their
FXS diagnosis
was confirmed
by southern
blot and they
had ADHD
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disorders.
Severe
medical,
surgical or
neurological
problems;
anything that
would
interfere with
treatment or
assessment; a
prior history of
Carnitine
therapy in the
past three
months prior
to baseline
Were not
included in the
study if they
had disorders
of central
nervous
system other
than FXS,
excluding
epilepsy

31

Acetyl –lCarnitine

7

Acetyl –lCarnitine

Outcomes
In study conducted by Abbasi et al. from 2011, the outcomes were measured
using the Parent and Teacher ADHD Scale IV that has been used in Iran in school-age
children. This scale measures the behavior and attention of the child and determines if it
is abnormal. In this study, the behavior and attention of patients were assessed at baseline
and then again at 21 days and then at 42 days after the medications were started. This
study also measured side effects such as psychic, neurologic, autonomic and other side
effects to determine how safe this medication was. The side effects were measured using
the mean decrease in ADHD-RS-IV score that evaluates 18 symptoms of ADHD.
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In the study conducted by Arnold et al. from 2007, a clinical evaluation was
performed using the placebo or acetyl-l-carnitine for 16 weeks total. The children were
evaluated at baseline, then at 8 weeks, then at 12 weeks and then again at 16 weeks using
the Parent and Teacher Rated Scales. The behavior and attention was recorded as well as
the safety measures including adverse reactions at 8, 12 and 16 weeks.
In the study conducted by Torrioli et al. from 2008, an evaluation of the behavior
and attention of boys with ADHD and Fragile X syndrome, was performed and they were
treated with either the placebo or acetyl-l-carnitine. In this study, the assessment used to
evaluate the boys was the Conners’ Global Index-Parents and Conners’ Global Index –
Teachers Scale. Results were also recorded from the Vineland scores as well. The boys
that remained in the study were evaluated at baseline, then at 1 week, then at 6 weeks and
then again at 12 weeks.
Results
In study conducted by Abbasi et al. 2011, a trial was conducted using children and
adolescents aged 7 to 13 years old. The total number of people in the study was 40
patients, which included 28 boys and 12 girls, all of whom had ADHD.1 The dose of the
methylphenidate and the Acetyl-L-Carnitine that the children were receiving was
dependent on their weight. The doses of these medications ranged from 20 to 30 mg a
day for the methylphenidate medication.1 In the first group, which was the group being
treated with ALC and methylphenidate, one patient dropped out. In the second group,
being treated with methylphenidate and the placebo, one patient also dropped out as well.
In this study the principal measure that evaluated the behavior of the children was the
Teacher and Parent attention deficit and hyperactivity disorder rating scale –IV.1 It was
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proven in this study that overall the Acetyl – L- Carnitine did not make a difference in the
behavior and attention of these children.1 It was shown that there was no difference
between the two groups on the following scales. The side effects of ALC was also
evaluated and it was shown that the group taking methylphenidate plus the placebo had
more headaches and irritability than the group taking methylphenidate and ALC. The
mean standard deviations scales were recorded and evaluated at baseline, and there was
no difference between the two groups.1 As time went on, according to a one way repeated
measures of analysis, the treatment that both groups were receiving did seem to greatly
impact their behavior and attention on the Parent ADHD Rating Scale scores but the
behavior between both groups was not that different.1 At the end of the study, the
standard deviation for the Parent ADHD Rating Scale for the group receiving ALC and
methylphenidate was -12.25± 9.86 and it was -10.35± 9.62 for the group receiving
methylphenidate plus the placebo.1 The children were again evaluated at 6 weeks and it
was determined that there was no difference in the behavior between the two groups
again. It was also determined that there was no major difference in attention on the
Teacher ADHD Rating Scale at baseline or at week 6 as well.1 Throughout the whole
study, the behavior and the attention of both groups was very similar and did not change
much between both groups, which lead to the results of the ALC not being effective.1 At
the end of the study, the standard deviation for the Teacher ADHD Rating Scale scores
for the group receiving ALC and methylphenidate was -7.90± 10.13 and it was -6.00±
7.84 for the group receiving methylphenidate plus the placebo.1 This study did not only
evaluate the effectiveness of the drug but also the side effects and safety. This study
evaluated side effects such as abdominal pain, anxiety, decreased appetite, depression,
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insomnia, weight loss, nausea, dry mouth, irritability, headaches, vomiting, fatigue,
diarrhea, and dizziness. It was determined that the group receiving the methylphenidate
and the placebo experienced more headaches and irritability.1 The group receiving
methylphenidate and the placebo contained 19 people total and out of 19 patients, 18 of
them experienced irritability, while 12 of them experienced headaches. 1 The value here
was small. The NNH for the side effects, such as headaches was -3. That means for every
3 patients treated with ALC, 1 fewer patient experienced side effects, such as headaches.	
  
At the end of this study, it was determined that ALC plus methylphenidate helped to
prevent side effects such as headaches and irritability.
In the study conducted by Arnold et al. 2007, the total number of participants was
112 children, which contained 83 boys and 29 girls, aged 5 to 12 years old diagnosed
with ADHD.2 The intent to treat analysis, 9 DSM-IV Teacher Rated Inattentive
Symptoms Scale, determined that using ALC alone without any other medications, was
not effective and did not have a great impact on the behavior and attention of the children
in this study.2 Out of the 112 children that entered the study, only 92 children completed
the assessment that took 8 weeks and 81 children completed the whole study.2 The
primary outcome measure showed that ALC does help to improve the behavior and
attention of the child but the results were not significant enough to consider this treatment
successful. The primary outcome measure was the ITT outcome, which was the Teacher
Rated Inattention Scale.2 Data from this primary outcome measure showed that there was
no significant difference between the group taking the ALC and the group taking just the
placebo. ITT analyses of secondary measure also reported finding the same results stating
that there was not much of a difference between both groups as well. Another primary
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outcome measure, known as the ADHD Inattentive Symptoms Scale, showed significant
effects of ALC working well in children. According to these primary outcome measures,
the ALC worked better in children with the inattentive type of ADHD compared to how it
worked in children with the combined type of inattention and hyperactivity.2 This
primary outcome measure reported a p-value of 0.02 for the group of children being
treated with the ALC, which proved the data to be significant.2 This article also reported
on the side effects of the ALC compared to the placebo. The side effects observed in the
group being treated with ALC compared to the group being treated with the placebo,
were not significant and were not different between the two groups.2 This article reported
on side effects such as gastrointestinal disorders, headache, infections, cough,
musculoskeletal disorders, metabolism and nutrition disorders, psychiatric disorders,
poisoning, nasal congestion ands skin disorders. In the group of children being treated
with ALC there was a total of 58 children but only 42 completed the trial out of this
group.2 In the group being treated with the placebo, there were 60 children and only 39
completed the trial.2 The NNH calculated was 10 patients. That means for every 10
patients treated with ALC, 1 more patient experienced side effects, such as headaches.
The value here is large. The only significant finding from the study showed that the
children being treated with ALC were more prone to headaches compared to the group
being treated with the placebo, which was the opposite of what was found in the study
conducted by Abbasi et al. 2011.2
In the study conducted by Torrioli et al. 2008, the objective of the results was to
see if ALC would be effective in treating young boys with not only ADHD but also
Fragile X Syndrome. 63 males entered the study and the study eventually ended with 7
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patients dropping out leaving 56 patients to complete one year worth of treatment.3 The
patients were evaluated at baseline, then at 1 month, then at 6 months and then again in
12 months. In this study, according to the physicians’ ratings, it was determined that the
ALC was safe to use in this population with a very low number of side effects being
reported.3 This study used mean values and confidence intervals to record the data of both
groups. According to the Conners’ Parents Scale, responsible for measuring
inattentiveness, socialization and behavior, the score decreased 8 points in the group of
children being treated with the ALC and 4.4 points in the group being treated with the
placebo.3 The p-value recorded for this difference was 0.05, which was considered to be
significant. Due to the fact that these scores decreased, this proved that the behavior and
the inattentiveness of these young boys greatly improved.3 According to the Conners’
Teachers’ Scale, the score decreased as well by -6.2 points in the group being treated
with ALC and -5.6 points in the group being treated with the placebo, in a 12 month
period.3 This difference was considered insignificant due to the fact that this difference
produced a p-value of 0.041.3 This insignificant finding was probably due to the fact that
fewer teachers were able to respond to the questionnaires. The Vineland ABC and the
Vineland Socialization Scales were also used as well and these scales help determine that
the boys treated with ALC, had great improvements in their attention and socialization
skills compared to the group of boys treated with just the placebo.3 The scores of the
Vineland ABC and the Vineland Socialization Scales both increased but it increased
more in the group being treated with ALC by +2.3 and +6.6 points respectively.3 In the
group that contained the boys being treated with the placebo, they ended up losing all of
their improved skills and actually fell well below their starting points.3
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Discussion
ADHD is a disorder that is becoming more common but also is more recognized
today as a condition that really affects a child’s ability to learn. Research suggest that one
of the things that could lead to ADHD is the child’s ability to metabolize fatty acids and
phospholipids, which are needed for brain development.1 It was shown that in children
with ADHD, the levels of fatty acids are decreased in the plasma.1 ADHD is usually
treated with stimulants, which are the first line medications but it is not guaranteed that
these medications will always work. This urged scientists to find a different type of
medication that can treat the problem instead of only treating the symptoms. Studies also
show that diet and exercise play a big part in the development of ADHD and that needs to
be addressed as well. It was proven that ALC can effect neurotransmitter metabolism by
decreasing the glutamate dehydrogenase activity and increasing cytochrome oxidase
activity.1 Because of this reason, the goal of study conducted by Abbasi et al. from 2011,
was to prove that ALC can improve the metabolization of methylphenidate in children
with ADHD. Unfortunately, according to the results of this study, it was proven that
giving ALC along with methylphenidate was not helpful. But on the other hand, it was
shown that children in the group treated with methylphenidate and ALC, were shown to
have fewer side effects such as headaches and irritability than the group treated with the
placebo and methylphenidate.1 Although, results in other studies were quite different
showing that ALC decreased impulsive and hyperactive behavior in children.
According to the study by Torrioli et al. 2008, the results showed that the ALC
was effective towards improving the inattentive and social behavior in the male children
with FXS.3 Although, it was proven that the ALC did not actually improve or increase the
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intelligence of these boys.3 The children treated with the placebo also showed
improvement but not nearly as much as the group treated with the ALC. Other therapies
seem to help improve behavior too, along with the ALC, such as physical, speech and
occupational therapy and support from teachers and parents.3 In this study, the ALC
treatment helped to improve the hyperactive behavior but not enough to produce positive
results and one reason for this could be due to the fact that only 34 patients were scored
out of the 51.3 Since most of this study took place during the summer holiday months,
some appointments to assess the children were missed. It was noticed that in the Vineland
scores, the hyperactive group of children did well with the placebo during the first month
but then afterwards the behavior started to worsen, probably due to the placebo effect.3
The children, parents and teachers probably over estimated how well the drug would
work in the first month and then started to notice that afterwards it just was not working
at all.3
According to study by Arnold et al. 2007, different malfunctions located in the
brain can cause different types of ADHD. For example, research shows that the
inattentive type is caused increased activation of the anterior cingulate and the middle
frontal gyrus, which means there is a delay in the function of the thalamus.2 In other
words, another study can be performed testing the ALC treatment with just children who
have the inattentive type and this may produce better results. Other research shows the
combined type is caused by the activation of the thalamus, putamen and insula, which
would not benefit from ALC treatment.2 According to study by Torrioli et al. 2008,
research shows that ALC can increase the synthesis of acetylcholine, which would also
increase dopamine levels and various other amino acids needed for brain development.3
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There are several factors that come into play that could have affected the results,
such as short duration, small sample size, and doses of the medications used. 1,2,3 These
results are very similar to the results of study by Arnold et al. 2007. In study by Arnold et
al. 2007, it was proven that ALC was not effective in treating children with ADHD
because it showed no difference in behavior in these children compared to the children
being treated with the placebo.2 There are several factors that could play into the
outcomes and one of them being which type of ADHD does the child have. It was proven
that overall ALC was not an effective for ADHD treatment, however it was also proven
that the ALC worked better in children with the inattentive type of ADHD and was more
ineffective for children with the combined type.2,3 This study only included children of
upper and middle class families, but it probably would have been beneficial to include
children of lower class families as well to have better rounded results.2 Dosage of
medications in this study could have affected the results as well. Patients could have been
noncompliant with taking their medications, some medications could have been defective
or there could have been miscalculation in the initial dosing.1,2,3
There are also others factors that could have affected the results but not counted
for in this study such as season, diet, culture and geographic location. Three sites located
near the Eastern part of the Central Plains showed that the children being treated with the
ALC showed improvement in behavior compared to the group being treated with the
placebo.2 The other sites that were also included in this study showed results only
opposite of this. In the group of children being treated with the ALC, it contained more
children in the inattentive group compared to the combined group. In the group being
treated with the placebo, it had an equal number of children in both the inattentive group
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and the combined group.2 This variable in the number of children being treated with the
ALC definitely could have played a part in the failure of this study, leading to an unfair
advantage for the placebo.2

Conclusion
In the end, it was determined that combined with methylphenidate, ALC would
not be considered an effective treatment to help improve the behavior of children with
ADHD. ALC, however, was found to have beneficial effects in reducing side effects such
as headaches and irritability. ALC used alone without any other medication was also
determined to be ineffective in treating the behavior symptoms of ADHD. ALC was
proven to have great improvement in the inattention and social skills of children, not only
with ADHD, but also with Fragile X Syndrome.
Further research can and should be explored, evaluating the effects ALC
treatment in children with autism, who cannot tolerate stimulants. It was also determined
that ALC is safe to use for treatment of ADHD without harmful side effects. In two out of
the three articles discussed, it was found that ALC actually might be more beneficial for
treatment for a certain type of ADHD, like the inattentive type. Further research should
also be done exploring ALC as a potential treatment for children and adolescents, who
only have the inattentive ADHD. There are many factors that could have a played a role
in this failure in two out of the three studies, such as the sample size, location, economic
status, dosage of medications, compliancy, and the measuring analysis.
Research supports that one of the main reasons that cause inattentive ADHD was
a decrease in the levels of fatty acids being produced and absorbed. This research
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supports the theory that ALC can be used to help increase energy levels of these children
that have the inattentive type of ADHD by stimulating lipid production or increasing the
absorption of the lipids in different portions of the brain. It has also been found that this
supplement can help increase levels of acetylcholine by increasing the cytochrome
oxidase activity. With further research, ALC may be proven to improve the lives of
children with the inattentive type of ADHD and other conditions such as autism.
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